Apellis Pharmaceuticals, INC 10-Q quarterly reports

Apellis Pharmaceuticals announced strong Q1 2026 revenue growth driven by its key drugs, SYFOVRE and EMPAVELI, while progressing towards its acquisition by Biogen.

Apellis Pharmaceuticals reported a significant swing to net income in Q3 2025, driven by a $275 million upfront payment from a royalty buy-down agreement with Sobi, alongside stable SYFOVRE sales and new EMPAVELI indications.

Apellis Pharmaceuticals reported increased net losses and decreased product revenue for the second quarter and first half of 2025, but secured significant liquidity through a royalty buy-down agreement and gained a new FDA approval for EMPAVELI.

Apellis Pharmaceuticals' Q1 2025 results reveal a decrease in SYFOVRE sales due to higher rebates and EMPAVELI revenue decline due to oral competition, despite progress in clinical trials and regulatory submissions.

Apellis Pharmaceuticals' Q3 2024 results show significant revenue growth driven by Syfovre sales, alongside updates on clinical programs and financial activities.

Apellis Pharmaceuticals' second quarter results show significant revenue growth, primarily driven by increased sales of their geographic atrophy treatment, Syfovre.

Apellis Pharmaceuticals saw a significant increase in revenue in the first quarter of 2024, primarily driven by the strong performance of its geographic atrophy treatment, Syfovre.